BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 28288138)

  • 1. MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer.
    Bouillez A; Rajabi H; Jin C; Samur M; Tagde A; Alam M; Hiraki M; Maeda T; Hu X; Adeegbe D; Kharbanda S; Wong KK; Kufe D
    Oncogene; 2017 Jul; 36(28):4037-4046. PubMed ID: 28288138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
    Lin PL; Wu TC; Wu DW; Wang L; Chen CY; Lee H
    Eur J Cancer; 2017 Nov; 85():95-105. PubMed ID: 28892778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evodiamine suppresses non-small cell lung cancer by elevating CD8
    Jiang ZB; Huang JM; Xie YJ; Zhang YZ; Chang C; Lai HL; Wang W; Yao XJ; Fan XX; Wu QB; Xie C; Wang MF; Leung EL
    J Exp Clin Cancer Res; 2020 Nov; 39(1):249. PubMed ID: 33208183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer.
    Wang J; Jia Y; Zhao S; Zhang X; Wang X; Han X; Wang Y; Ma M; Shi J; Liu L
    Oncogene; 2017 Nov; 36(45):6235-6243. PubMed ID: 28714960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells.
    Guo R; Li Y; Wang Z; Bai H; Duan J; Wang S; Wang L; Wang J
    Cancer Sci; 2019 May; 110(5):1665-1675. PubMed ID: 30844110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ubiquitin C-terminal hydrolase L1 promotes expression of programmed cell death-ligand 1 in non-small-cell lung cancer cells.
    Mao R; Tan X; Xiao Y; Wang X; Wei Z; Wang J; Wang X; Zhou H; Zhang L; Shi Y
    Cancer Sci; 2020 Sep; 111(9):3174-3183. PubMed ID: 32539182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNγ signaling in non-small cell lung cancer.
    Theelen WSME; Kuilman T; Schulze K; Zou W; Krijgsman O; Peters DDGC; Cornelissen S; Monkhorst K; Sarma P; Sumiyoshi T; Amler LC; Willems SM; Blaauwgeers JLG; van Noesel CJM; Peeper DS; van den Heuvel MM; Kowanetz M
    PLoS One; 2019; 14(5):e0216864. PubMed ID: 31125352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer.
    Maeda T; Hiraki M; Jin C; Rajabi H; Tagde A; Alam M; Bouillez A; Hu X; Suzuki Y; Miyo M; Hata T; Hinohara K; Kufe D
    Cancer Res; 2018 Jan; 78(1):205-215. PubMed ID: 29263152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanistic Insights of Anti-Immune Evasion by Nobiletin through Regulating miR-197/STAT3/PD-L1 Signaling in Non-Small Cell Lung Cancer (NSCLC) Cells.
    Sp N; Kang DY; Lee JM; Jang KJ
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MYC expression correlates with PD-L1 expression in non-small cell lung cancer.
    Kim EY; Kim A; Kim SK; Chang YS
    Lung Cancer; 2017 Aug; 110():63-67. PubMed ID: 28676221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.
    Chen N; Fang W; Zhan J; Hong S; Tang Y; Kang S; Zhang Y; He X; Zhou T; Qin T; Huang Y; Yi X; Zhang L
    J Thorac Oncol; 2015 Jun; 10(6):910-23. PubMed ID: 25658629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer.
    Chao YC; Lee KY; Wu SM; Kuo DY; Shueng PW; Lin CW
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine.
    Wrangle J; Wang W; Koch A; Easwaran H; Mohammad HP; Vendetti F; Vancriekinge W; Demeyer T; Du Z; Parsana P; Rodgers K; Yen RW; Zahnow CA; Taube JM; Brahmer JR; Tykodi SS; Easton K; Carvajal RD; Jones PA; Laird PW; Weisenberger DJ; Tsai S; Juergens RA; Topalian SL; Rudin CM; Brock MV; Pardoll D; Baylin SB
    Oncotarget; 2013 Nov; 4(11):2067-79. PubMed ID: 24162015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy enhances programmed cell death 1/ligand 1 expression via TGF-β induced epithelial mesenchymal transition in non-small cell lung cancer.
    Funaki S; Shintani Y; Kawamura T; Kanzaki R; Minami M; Okumura M
    Oncol Rep; 2017 Oct; 38(4):2277-2284. PubMed ID: 28849209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Morphine-3-glucuronide upregulates PD-L1 expression
    Wang K; Wang J; Liu T; Yu W; Dong N; Zhang C; Xia W; Wei F; Yang L; Ren X
    Cancer Biol Med; 2021 Feb; 18(1):155-171. PubMed ID: 33628591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bu Fei Decoction attenuates the tumor associated macrophage stimulated proliferation, migration, invasion and immunosuppression of non-small cell lung cancer, partially via IL-10 and PD-L1 regulation.
    Pang L; Han S; Jiao Y; Jiang S; He X; Li P
    Int J Oncol; 2017 Jul; 51(1):25-38. PubMed ID: 28534943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer.
    Larsen TV; Hussmann D; Nielsen AL
    Cancer Commun (Lond); 2019 Jun; 39(1):30. PubMed ID: 31159869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circular RNA hsa_circ_0000190 Facilitates the Tumorigenesis and Immune Evasion by Upregulating the Expression of Soluble PD-L1 in Non-Small-Cell Lung Cancer.
    Luo YH; Yang YP; Chien CS; Yarmishyn AA; Adekunle Ishola A; Chien Y; Chen YM; Tsai PH; Lin TW; Wang ML; Chiou SH
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer.
    Kim DH; Kim H; Choi YJ; Kim SY; Lee JE; Sung KJ; Sung YH; Pack CG; Jung MK; Han B; Kim K; Kim WS; Nam SJ; Choi CM; Yun M; Lee JC; Rho JK
    Exp Mol Med; 2019 Aug; 51(8):1-13. PubMed ID: 31399559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.
    Büttner R; Gosney JR; Skov BG; Adam J; Motoi N; Bloom KJ; Dietel M; Longshore JW; López-Ríos F; Penault-Llorca F; Viale G; Wotherspoon AC; Kerr KM; Tsao MS
    J Clin Oncol; 2017 Dec; 35(34):3867-3876. PubMed ID: 29053400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.